COMPARISON OF MOVEMENT CHARACTERISTIC AND MUSCLE ACTIVATION BETWEEN DIFFERENT FITNESS HOOPS

Purpose: To compare the movement characteristics and muscle activation between Hula Hoop (HL) and Mini Hoop (MH). Methods: Sixteen healthy females randomly used HL and MH three minutes, respectively. Motion Analysis System and Noraxon wireless surface electromyography (EMG) were used to measure the movement characteristics and muscle activation. The paired t-test was used to test the difference between MH and HL. Results: The HL had larger in range of hip motion and root mean square of EMG in spinal erectors than MH (p < .05); the MH had higher in movement frequency (cycles per second) and median frequency of EMG in spinal erectors than HL (p < .05). Conclusion: Two fitness hoops have different movement characteristics and muscle action due to the different equipment design

EFFECT OF EIGHT WEEKS VIBRATION TRAINING ON THE LOWER LIMB BASIC ABILITY AND ATHLETIC PERFORMANCE OF GYMNASTS

The purpose of this study explores the effects of 8 weeks vibration training on the basic ability (explosive power, speed, agility) and athletic performance (backward somersault) of the lower limbs of gymnasts. Sixteen gymnasts were randomly divided into vibration training group (VT) and control group (CON). Participants were trained for eight weeks and performed countermovement jump (CMJ), sprints, shuttle run, and backward somersault tests before the training, after 4 weeks, and 8 weeks of training. The significant level was set to α = .05. The results showed that the speed of VT increased significantly after 4 weeks of training, and the speed and agility of VT increased significantly after 8 weeks of training (p \u3c.05). In conclusion, Gymnasts can improve their speed ability through 4 weeks of vibration training, and 8 weeks vibration training can improve their speed and agility

Nonlinear 3D Model of Double Shear Lap Tests for the Bond of Near-surface Mounted FRP Rods in Concrete Considering Different Embedment Depth

The utilization of near-surface mounted Fiber Reinforced Polymer (FRP) reinforcement as a method of strengthening in reinforced concrete structures has increased considerably in recent years. Moreover, the application of double-shear lap tests for this rein-forcement method leads to the achievement of a local bond-slip behavior in a bonded joint. This research, therefore, focused on 3-D modeling of this type of test to suitably characterize the bond mechanics between FRP rods and concrete at various embedment depth. The use of different alternatives to represent the interface between the FRP rod and concrete were analyzed after which a&nbsp;comparison was drawn between the numerical finite element (FE) simulations and experimental measurements. The results showed the prediction of the load–slip corresponded with the data obtained from the experiment. Finally, the proposed model has the ability to express the relationship between the penalty stiffness parameters in shear direction Kss = (Ktt) and the embedment depth of FRP rods

Formulating Seismic Intensity Scale (JMA-SIS) Using Response Spectrum: A New Approach for Structural Engineering Design

This study aims to formulate a calculation for earthquake shaking intensity (rs_mSIS) based on the response spectrum (RS) using the Japan Meteorological Agency-seismic intensity scale. The research investigates the relationship between the response spectrum parameters—period and maximum acceleration—and the earthquake source types, including megathrust, Benioff, and shallow crust/background sources. Artificial ground motions are generated and analyzed using Matlab to calculate shaking intensity values, which are then used to develop the rs_mSIS formula. The formulation is validated against actual response spectrum data from 15 Indonesian cities and demonstrated high accuracy, with the Wariyatno coefficient applicable across all models. This approach provides a standardized method to assess seismic intensity, offering enhanced reliability for building design in earthquake-prone areas and serving as a valuable tool for engineers and urban planners to improve earthquake resilience in diverse seismic environments

Defibrotide modulates pulmonary endothelial cell activation and protects against lung inflammation in pre-clinical models of LPS-induced lung injury and idiopathic pneumonia syndrome

IntroductionA multiple organ dysfunction syndrome (MODS) workshop convened by the National Institute of Child Health and Human Development in 2015 identified acute respiratory distress syndrome (ARDS) and complications of allogeneic blood and marrow transplantation (allo-BMT) as contributors to MODS in pediatric patients. Pulmonary dysfunction also remains a significant complication of allo-BMT. Idiopathic pneumonia syndrome (IPS) defines non-infectious, acute, lung injury that occurs post-transplant. Injury and activation to endothelial cells (ECs) contribute to each form of lung inflammation.MethodsTwo murine models were employed. In an ARDS model, naïve B6 mice receive an intravenous (i.v.) injection of lipopolysaccharide (LPS). In the established model of IPS, naïve B6D2F1 mice receive lethal total body irradiation followed by BMT from either allogeneic (B6) or syngeneic (B6D2F1) donors. Lung inflammation was subsequently assessed in each scenario.ResultsIntravenous injection of LPS to B6 mice resulted in enhanced mRNA expression of TNFα, IL-6, Ang-2, E-, and P-selectin in whole lung homogenates. The expression of Ang-2 in this context is regulated in part by TNFα. Additionally, EC activation was associated with increased total protein and cellularity in broncho-alveolar lavage fluid (BALF). Similar findings were noted during the development of experimental IPS. We hypothesized that interventions maintaining EC integrity would reduce the severity of ARDS and IPS. Defibrotide (DF) is FDA approved for the treatment of BMT patients with sinusoidal obstruction syndrome and renal or pulmonary dysfunction. DF stabilizes activated ECs and protect them from further injury. Intravenous administration of DF before and after LPS injection significantly reduced mRNA expression of TNFα, IL6, Ang-2, E-, and P-selectin compared to controls. BALF showed decreased cellularity, reflecting less EC damage and leak. Allogeneic BMT mice were treated from day -1 through day 14 with DF intraperitoneally, and lungs were harvested at 3 weeks. Compared to controls, DF treatment reduced mRNA expression of TNFα, IL6, Ang-2, E-, and P- selectin, BALF cellularity, and lung histopathology.ConclusionThe administration of DF modulates EC injury in models of ARDS and IPS. Cytokine inhibition in combination with agents that stabilize EC integrity may be an attractive strategy for patients in each setting

Paeonol Attenuates Cigarette Smoke-Induced Lung Inflammation by Inhibiting ROS-Sensitive Inflammatory Signaling

Cigarette smoking causes persistent lung inflammation that is mainly regulated by redox-sensitive pathways. We have previously reported that cigarette smoke (CS) activates reactive oxygen species- (ROS-) sensitive mitogen-activated protein kinases (MAPKs)/nuclear factor-κB (NF-κB) signaling leading to induction of lung inflammation. Paeonol, the main phenolic compound present in the Chinese herb Paeonia suffruticosa, has antioxidant and anti-inflammatory properties. However, whether paeonol has similar beneficial effects against CS-induced lung inflammation remains unclear. Using a murine model, we showed that chronic CS exposure for 4 weeks caused pulmonary inflammatory infiltration, increased lung vascular permeability, elevated lung levels of chemokines, cytokines, and 4-hydroxynonenal (an oxidative stress biomarker), and induced lung inflammation; all of these CS-induced events were suppressed by chronic treatment with paeonol. Using human bronchial epithelial cells (HBECs), we demonstrated that cigarette smoke extract (CSE) sequentially increased extracellular and intracellular levels of ROS, activated the MAPKs/NF-κB signaling, and induced interleukin-8 (IL-8); all these CSE-induced events were inhibited by paeonol pretreatment. Our findings suggest a novel role for paeonol in alleviating the oxidative stress and lung inflammation induced by chronic CS exposure in vivo and in suppressing CSE-induced IL-8 in vitro via its antioxidant function and an inhibition of the MAPKs/NF-κB signaling

Association of Suicide Risk With Headache Frequency Among Migraine Patients With and Without Aura

Background: Migraines with aura have been associated with suicide in adolescents and young adults, but the association between suicide and migraine frequency has not been determined. This study investigated suicidal ideation and suicide attempts among patients with varying frequencies of migraines, with and without auras.Methods: This cross-sectional study analyzed 528 patients aged between 20 and 60 years from a headache outpatient clinic in Taiwan. All patients completed a set of questionnaires, including a demographic questionnaire, the Migraine Disability Assessment questionnaire, the Hospital Anxiety and Depression Scale, the Beck Depression Inventory, and the Pittsburgh Sleep Quality Index. Suicide risk was evaluated by self-reported lifetime suicidal ideation and attempts. Patients were divided into low-frequency (1–4 days/month), moderate-frequency (5–8 days/month), high-frequency (9–14 days/month), and chronic (≥15 days/month) migraine groups. The association between migraine frequency and suicidality was investigated using multivariable linear regression and logistic regression.Results: The rates of suicidal ideation and suicide attempts were the highest for chronic migraine with aura (ideation: 47.2%; attempts: 13.9%) and lowest in migraine-free controls (2.8%). Migraine frequency was an independent risk factor for suicidal ideation and attempts in patients with aura (both Ptrend &lt; 0.001), but not in patients without auras. Migraine aura and depression were associated with higher risks of suicidal ideation and suicide attempts in patients with migraine.Conclusion: High migraine frequency has a correlation with high suicide risk in patients who experience an aura, but not in other patients with migraine

Association between the risk of heart failure hospitalization and end-stage renal disease with digoxin usage in patients with cardiorenal syndrome: A population-based study

BackgroundThe management of the coexistence of heart disease and kidney disease is increasingly challenging for clinicians. Chronic kidney disease (CKD) is not only a prevalent comorbidity of patients with heart failure but has also been identified as a noteworthy risk factor for all-cause mortality and poor clinical outcomes. Digoxin is one of the commonest treatments for heart disease. There are few trials investigating the role of digoxin in patients with cardiorenal syndrome (CRS). This study aims to examine the association between digoxin usage and clinical outcomes in patients with CRS in a nationwide cohort.MethodWe conducted a population-based study that included 705 digoxin users with CRS; each patient was age, sex, comorbidities, and medications matched with three non-users who were randomly selected from the CRS population. Cox proportional hazards regression analysis was conducted to estimate the effects of digoxin on the incidence of all-cause mortality, congestive heart failure (CHF) hospitalization, coronary artery disease (CAD) hospitalization, and end-stage renal disease (ESRD).ResultsThe all-cause mortality rate was significantly higher in digoxin users than in non-users (adjusted hazard ratio [aHR] = 1.26; 95% confidence interval [CI] = 1.09–1.46, p = 0.002). In a subgroup analysis, there was significantly high mortality in the 0.26–0.75 defined daily dose (DDD) subgroup of digoxin users (aHR = 1.49; 95% CI = 1.23–1.82, p&lt;0.001). Thus, the p for trend was 0.013. With digoxin prescription, the CHF hospitalization was significantly higher [subdistribution HR (sHR) = 1.17; 95% CI = 1.05–1.30, p = 0.004], especially in the &gt;0.75 DDD subgroup (sHR = 1.19; 95% CI = 1.01–1.41, p = 0.046; p for trend = 0.006). The digoxin usage lowered the coronary artery disease (CAD) hospitalization in the &gt; 0.75 DDD subgroup (sHR = 0.79; 95% CI = 0.63–0.99, p = 0.048). In renal function progression, more patients with CRS entered ESRD with digoxin usage (sHR = 1.34; 95% CI = 1.16–1.54, p&lt;0.001). There was a significantly greater incidence of ESRD in the &lt; 0.26 DDD and 0.26–0.75 DDD subgroups of digoxin users (sHR = 1.32; 95% CI = 1.06–1.66, p = 0.015; sHR = 1.44; 95% CI = 1.18–1.75; p for trend&lt;0.001).ConclusionDigoxin should be prescribed with caution to patients with CRS